ESSER/GEER Relief Funds: Know what funding you are eligible for
You may be eligible for new CARES Act funds to upgrade student safety. Congress approved a second pandemic relief bill with $81.9 billion dedicated to help support educational institutions – including a $54.3 billion Elementary and Secondary Emergency Relief Fund (ESSER), and a $1.3 billion Emergency Education Relief Fund (GEER).
Download our whitepaper to learn:
- What funding is available and the eligibility criteria
- The school bus technologies districts can apply to receive ESSER and GEER grants for
- What these technologies can mean to your school district today and how they can drive value beyond COVID-19
LEARN MORE ABOUT ESSER/GEER COVID-19 RELIEF FUNDING
ESSER/GEER Relief Funds: Know what funding you are eligible for
You may be eligible for new CARES Act funds to upgrade student safety. Congress approved a second pandemic relief bill with $81.9 billion dedicated to help support educational institutions – including a $54.3 billion Elementary and Secondary Emergency Relief Fund (ESSER), and a $1.3 billion Emergency Education Relief Fund (GEER).
Download our whitepaper to learn:
- What funding is available and the eligibility criteria
- The school bus technologies districts can apply to receive ESSER and GEER grants for
- What these technologies can mean to your school district today and how they can drive value beyond COVID-19
LEARN MORE ABOUT ESSER/GEER COVID-19 RELIEF FUNDING
Eligible funds from ESSER and GEER could be used to help your school district invest in new technology to:
- Make student contact tracing easier
- Enable distance learning and mobile classrooms
- Verify COVID-19 disinfection/vehicle inspections
- Get better insight into onboard behavior
Safe Fleet technology can be used as stand-alone solutions to help a school district respond to COVID-19. Each of these solutions can also be used in combination with other Safe Fleet safety systems or in the form of an integrated Connected School Bus for enhanced and rapid response to COVID-19 scenarios.